|
WO2020225740A1
|
|
Pharmaceutical combination comprising trazodone for the treatment of neuropathic pain
|
|
WO2020178316A1
|
|
5- or 7-azaindazoles as beta-lactamase inhibitors
|
|
WO2020074463A1
|
|
Oral liquid composition comprising triptan
|
|
EP3807293A1
|
|
Peptides having inhibitory activity on neuronal exocytosis
|
|
EP3807294A1
|
|
Peptides having inhibitory activity on muscarinic receptor m3
|
|
KR20210005863A
|
|
1H-indazole-3-carboxamide compound as a glycogen synthase kinase 3 beta inhibitor
|
|
EP3749668A1
|
|
Continuous process for the preparation of trazodone
|
|
KR20200094161A
|
|
Stable liquid composition of ketoprofen, salts and enantiomers thereof
|
|
KR20190026686A
|
|
Pharmaceutical compositions comprising benzydamine
|
|
AU2017276627A1
|
|
New antibacterial compounds
|
|
BR112018071173A2
|
|
ophthalmic composition, method for treating dry eye syndrome, and process for preparing ophthalmic composition.
|
|
AU2017221053A1
|
|
Dispenser with articulated dispensing tube
|
|
US2018296553A1
|
|
Combination of trazodone and gabapentin for the treatment of pain
|
|
AU2016282260A1
|
|
Deodorant composition comprising a mixture of alpha, beta and gamma cyclodextrin
|
|
EP3064200A1
|
|
Composition comprising natural substances and/or extracts
|
|
KR20170101941A
|
|
Pharmaceutical Composition for the Treatment of Mycosis
|
|
HUE050749T2
|
|
Antibacterial compounds having broad spectrum of activity
|
|
WO2016096631A1
|
|
New antibacterial compounds
|
|
AU2015204274A1
|
|
Packaging material for a pharmaceutical product
|
|
AU2015204272A1
|
|
Packaging material for a pharmaceutical product and method for producing this material
|
